The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2-16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.

CeMM Research Center for Molecular Medicine of Austrian Academy of Sciences Vienna Austria

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Clinical Hematology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine 1 Division of Hematology and Blood Coagulation Medical University of Vienna Austria

Department of Internal Medicine Hematology and Oncology Faculty of Medicine Masaryk University Brno Czech Republic

See more in PubMed

Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670. PubMed

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907–3913. PubMed

Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441–447. PubMed

Sterkers Y, Preudhomme C, Laï JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616–622. PubMed

Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410–2415. PubMed PMC

Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia? Blood 1998; 92: 1459–1460, author reply 1460–1451. PubMed

Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52: 42–46. PubMed

Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997; 39: 11–18. PubMed

Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F. Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol 2012; 6: 149–152. PubMed PMC

Björkholm M, Hultcrantz M, Derolf Å. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol 2014; 27: 141–153. PubMed

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220–2228. PubMed

Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115: 2882–2890. PubMed PMC

Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447–452. PubMed PMC

Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119: 4480–4485. PubMed PMC

Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009; 114: 5201–5205. PubMed

Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369–370. PubMed

Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24: 1389–1402. PubMed PMC

Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008; 22: 1539–1541. PubMed

Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med 2011; 364: 488–490. PubMed

Neri A, Fracchiolla NS, Radaelli F, Boletini A, Ribera S, Migliorini C et al. p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia. Br J Haematol 1996; 93: 670–673. PubMed

Gaidano G, Guerrasio A, Serra A, Carozzi F, Cambrin GR, Petroni D et al. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 1993; 7: 946–953. PubMed

Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115: 2891–2900. PubMed

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: E5401–5410. PubMed PMC

Robles A, Harris C. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010; 2: a001016. PubMed PMC

Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Human Mutation 2014; 35: 663–671. PubMed

Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 2015; 29: 877–885. PubMed PMC

Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329. PubMed

Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famà R et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 123: 2139–2147. PubMed PMC

Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009; 94: 1762–1766. PubMed PMC

Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD et al. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget 2016; 7: 36266–36279. PubMed PMC

Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol 2010; 8: e1000324. PubMed PMC

Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552–555. PubMed PMC

Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010; 6: 309–322. PubMed PMC

Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 1968; 28: 1559–1565. PubMed

Nayak BK, Das GM. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene 2002; 21: 7226–7229. PubMed

Furgerson JL, Vukelja SJ, Baker WJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996; 51: 137–140. PubMed

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951. PubMed

van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317. PubMed

Vandenbroucke I, Van Marck H, Verhasselt P, Thys K, Mostmans W, Dumont S et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011; 51: 167–177. PubMed

Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003; 21: 313–320. PubMed

Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43 (Database issue): D805–811. PubMed PMC

R_Core_Team. R: A Language and Environment for Statistical Computing, 2015. Available at https://www.R-project.org.

Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450–454. PubMed

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390. PubMed

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J et al. TP53 variations in human cancers: new lessons from the IARC TP53 Database and Genomics Data. Hum Mutat 2016; 37: 865–876. PubMed

Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL, Béroud C. MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat 2010; 31: 1020–1025. PubMed

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488–2498. PubMed PMC

Marusyk A, DeGregori J. Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations. Biochim Biophys Acta 2008; 1785: 1–11. PubMed PMC

Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica 2010; 95: 2153–2156. PubMed PMC

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883–892. PubMed PMC

Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163: 496–500. PubMed

Tsuruta-Kishino T, Koya J, Kataoka K, Narukawa K, Sumitomo Y, Kobayashi H et al. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. Oncogene 2017; 36: 3300–3311. PubMed

Marusyk A, Wheeler LJ, Mathews CK, DeGregori J. p53 mediates senescence-like arrest induced by chronic replicational stress. Mol Cell Biol 2007; 27: 5336–5351. PubMed PMC

Gottifredi V, Shieh S, Taya Y, Prives C. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci USA 2001; 98: 1036–1041. PubMed PMC

Marusyk A, DeGregori J. Replicational stress selects for p53 mutation. Cell Cycle 2007; 6: 2148–2151. PubMed PMC

Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single-cell RNA sequencing

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options

CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

ToTem: a tool for variant calling pipeline optimization